Similar articles

• [TNF-alpha antagonist in rheumatoid arthritis. Joint destruction can be controlled].

  [No authors listed] [No authors listed] MMW Fortschr Med. 2003 Oct 9;145(41):46. MMW Fortschr Med. 2003. PMID: 14655484 German. No abstract available.
• Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review.

  Ariza-Ariza R, Navarro-Sarabia F, Hernández-Cruz B, Rodríguez-Arboleya L, Navarro-Compán V, Toyos J. Ariza-Ariza R, et al. Rheumatology (Oxford). 2007 Mar;46(3):529-32. doi: 10.1093/rheumatology/kel326. Epub 2006 Sep 29. Rheumatology (Oxford). 2007. PMID: 17012439 Review.
• Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.

  Ollendorf DA, Klingman D, Hazard E, Ray S. Ollendorf DA, et al. Clin Ther. 2009 Apr;31(4):825-35. doi: 10.1016/j.clinthera.2009.04.002. Clin Ther. 2009. PMID: 19446156
• Dose adjustment over time of etanercept and infliximab in patients with rheumatoid arthritis.

  Etemad L, Yu EB, Wanke LA. Etemad L, et al. Manag Care Interface. 2005 Apr;18(4):21-7. Manag Care Interface. 2005. PMID: 15889759
• Efficacy of treatment intensification with adalimumab, etanercept and infliximab in rheumatoid arthritis: a systematic review of cohort studies with focus on dose.

  Eng G, Stoltenberg MB, Szkudlarek M, Bouchelouche PN, Christensen R, Bliddal H, Marie Bartels E. Eng G, et al. Semin Arthritis Rheum. 2013 Oct;43(2):144-51. doi: 10.1016/j.semarthrit.2013.01.007. Epub 2013 Jul 6. Semin Arthritis Rheum. 2013. PMID: 23838092 Review.